SCHEMBL16646129

SCHEMBL16646129

O=S(=O)(Nc1nccs1)c1ccc(NCc2ccccc2O)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX12 P18054 7/20 0.74
PKM P14618 3/20 0.74
ALDH1A1 P00352 3/20 0.70
LMNA P02545 1/20 0.70
GAA P10253 1/20 0.70
MAPK1 P28482 1/20 0.70
KMT2A Q03164 2/20 0.66
MAPT P10636 1/20 0.66
L3MBTL1 Q9Y468 1/20 0.66
SCN3A Q9NY46 3/20 0.57
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA9 Q16790 1/20 0.56
MEN1 O00255 1/20 0.56
ATM Q13315 1/20 0.55
SCN1A P35498 2/20 0.54
SCN5A Q14524 2/20 0.54
SCN8A Q9UQD0 2/20 0.54
SCN4A P35499 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16646115 0.86 ALOX12 (0.67) ALOX12PKMALDH1A1LMNAGAA
SCHEMBL16646105 0.85 ALOX12 (1.00) ALOX12PKMALDH1A1LMNAGAA
SCHEMBL16646059 0.85 ALOX12 (1.00) ALOX12PKMALDH1A1LMNAGAA
SCHEMBL16646114 0.85 ALOX12 (0.85) ALOX12PKMALDH1A1LMNAGAA
SCHEMBL16646016 0.85 PKM (0.78) ALOX12PKMALDH1A1LMNAGAA
SCHEMBL16646058 0.85 ALOX12 (1.00) ALOX12PKMALDH1A1LMNAGAA
SCHEMBL18356429 0.85 ALOX12 (1.00) ALOX12PKMALDH1A1LMNAGAA
SCHEMBL16646062 0.85 PKM (0.78) ALOX12PKMALDH1A1LMNAGAA
SCHEMBL18356219 0.85 ALOX12 (0.78) ALOX12PKMALDH1A1LMNAGAA
SCHEMBL16646086 0.85 ALOX12 (1.00) ALOX12PKMALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024019959-A1 COMPOSITIONS FOR MODULATING LIPOXYGENASE AND METHODS OF USING SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-01-25 WO disclosed
EP-3054936-B1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS EASTERN VIRGINIA MEDICAL SCHOOL (US) 2023-10-18 EP disclosed
US-20200392077-A1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-12-17 US disclosed
US-10752581-B2 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase EASTERN VIRGINIA MEDICAL SCHOOL (US) 2020-08-25 US disclosed
US-20190276395-A1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-09-12 US disclosed
US-10266488-B2 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase EASTERN VIRGINIA MEDICAL SCHOOL (US) 2019-04-23 US disclosed
US-20170001955-A1 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase THOMAS JEFFERSON UNIVERSITY 2017-01-05 US disclosed
US-20170001955-A1 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase THOMAS JEFFERSON UNIVERSITY 2017-01-05 US disclosed
WO-2015054662-A1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS EASTERN VIRGINIA MEDICAL SCHOOL (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10266488-B2 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase ALOX12, ALOX15, ALOX15B ALOX12 1/4885PKM 2250/4885ALDH1A1 3051/4885
US-20200392077-A1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE ALOX12, ALOX15, ALOX15B ALOX12 1/4885PKM 2250/4885ALDH1A1 3051/4885
US-20190276395-A1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE ALOX12, ALOX15, ALOX15B ALOX12 1/4885PKM 2250/4885ALDH1A1 3051/4885
US-10752581-B2 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase ALOX12, ALOX15, ALOX15B ALOX12 1/4885PKM 2250/4885ALDH1A1 3051/4885
US-20170001955-A1 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase ALOX12, ALOX15, ALOX15B ALOX12 1/4885PKM 2250/4885ALDH1A1 3051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.